Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

Warren, Robert S.; Yuan, Hui; Matli, Mary; Gillett, Nancy A.; Ferrara, Napoleone

doi:10.1172/jci117857

Cited by 613 publications

(297 citation statements)

References 38 publications

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…Studies from our laboratory and others suggest that VEGF is the angiogenic factor that is most closely associated with induction and maintenance of the neovasculature in human colon cancer (Warren et al, 1995;Ellis et al, 1996;Takahashi et al, 1996). Our present results show that treatment of mice with EGCG resulted in marked inhibition of the growth, vascularity, and proliferation of human tumour xenografts in nude mice.…”

Section: Discussionsupporting

confidence: 67%

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells

et al. 2001

View full text Add to dashboard Cite

Catechins are key components of teas that have antiproliferative properties. We investigated the effects of green tea catechins on intracellular signalling and VEGF induction in vitro in serum-deprived HT29 human colon cancer cells and in vivo on the growth of HT29 cells in nude mice. In the in vitro studies, (-)-epigallocatechin gallate (EGCG), the most abundant catechin in green tea extract, inhibited Erk-1 and Erk-2 activation in a dose-dependent manner. However, other tea catechins such as (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG), and (-)-epicatechin (EC) did not affect Erk-1 or 2 activation at a concentration of 30 μM. EGCG also inhibited the increase of VEGF expression and promoter activity induced by serum starvation. In the in vivo studies, athymic BALB/c nude mice were inoculated subcutaneously with HT29 cells and treated with daily intraperitoneal injections of EC (negative control) or EGCG at 1.5 mg day −1 mouse −1 starting 2 days after tumour cell inoculation. Treatment with EGCG inhibited tumour growth (58%), microvessel density (30%), and tumour cell proliferation (27%) and increased tumour cell apoptosis (1.9-fold) and endothelial cell apoptosis (3-fold) relative to the control condition ( P < 0.05 for all comparisons). EGCG may exert at least part of its anticancer effect by inhibiting angiogenesis through blocking the induction of VEGF. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Section: Discussionsupporting

confidence: 67%

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Several studies have revealed that TAMs are a very critical cell group in tumor tissue and that TAMs contribute greatly to tumorigenesis and the protection of tumors from therapy (McDonnell et al, 2003). VEGF inhibition represses tumor angiogenesis, and this result has led to the clinical utilization of VEGF inhibitors to treat cancer (Warren et al, 1995;Presta et al, 1997). In our present study, we used a microvesicledelivered antagonucleotide against miR-150 to treat tumors.…”

Section: Microvesicle-delivered Mir-150 Inhibitor Prevents Tumorigenesismentioning

confidence: 99%

Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development

et al. 2013

View full text Add to dashboard Cite

“…Inhibition of VEGF protein with neutralising antibodies will decrease the rate of growth of liver metastasis from colon cancer in an animal model. 11 A greater understanding of the role of VEGF in the prostate may lead to potential therapeutic strategies for both benign and malignant disease. The aim of our study was to evaluate the level of VEGF expression with the aid of immunocytochemistry in specimens of prostate cancer and BPH.…”

Section: Introductionmentioning

confidence: 99%

Distribution of vascular endothelial growth factor (VEGF) in prostate disease

Walsh

Sriprasad

Hopster

et al. 2002

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M þ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimens. A positive result was indicated by area staining > 25% and þ 2 or þ 3 staining intensity. Positive epithelial staining was observed in 50% of BPH specimens and 56% of cancer specimens, while positive stromal staining was observed in 73% of BPH specimens and 30% of cancer specimens. This may reflect an active role for stromal VEGF in the pathological process of BPH.

show abstract

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

Abstract: 1995.95:1789-1797.)

Cited by 613 publications

References 38 publications

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells

Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development

Distribution of vascular endothelial growth factor (VEGF) in prostate disease

Contact Info

Product

Resources

About